[1] CHEN L K, WOO J, ASSANTACHAI P, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment[J]. J Am Med Dir Assoc, 2020, 21(3): 300-307.
[2] PETERMANN-ROCHA F, BALNTZI V, GRAY S R, et al. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis[J]. J Cachexia Sarcopenia Muscle, 2022, 13(1): 86-99.
[3] BAI A, XU W, SUN J, et al. Associations of sarcopenia and its defining components with cognitive function in community-dwelling oldest old[J]. BMC Geriatr, 2021, 21(1): 292.
[4] RAMSEY K A, ROJER A G M, D’ANDREA L, et al. The association of objectively measured physical activity and sedentary behavior with skeletal muscle strength and muscle power in older adults: a systematic review and meta-analysis[J]. Ageing Res Rev, 2021, 67: 101266.
[5] PODDAR J, PRADHAN M, GANGULY G, et al. Biochemical deficits and cognitive decline in brain aging: intervention by dietary supplements[J]. J Chem Neuroanat, 2019, 95: 70-80.
[6] MIGLIAVACCA E, TAY S K H, PATEL H P, et al. Mitochondrial oxidative capacity and NAD(+) biosynthesis are reduced in human sarcopenia across ethnicities[J]. Nat Commun, 2019, 10(1): 5808.
[7] CALVO-RODRIGUEZ M, KHARITONOVA E K, SNYDER A C, et al. Real-time imaging of mitochondrial redox reveals increased mitochondrial oxidative stress associated with amyloid β aggregates in vivo in a mouse model of Alzheimer’s disease[J]. Mol Neurodegener, 2024, 19(1): 6.
[8] LIU Z J, ZHU C F. Causal relationship between insulin resistance and sarcopenia[J]. Diabetol Metab Syndr, 2023, 15(1): 46.
[9] MILSTEIN J L, FERRIS H A. The brain as an insulin-sensitive metabolic organ[J]. Mol Metab, 2021, 52: 101234.
[10] NGUYEN T T, TA Q T H, NGUYEN T T D, et al. Role of insulin resistance in the Alzheimer’s disease progression[J]. Neurochem Res, 2020, 45(7): 1481-1491.
[11] JARMUSCH S, BABER L, BIDLINGMAIER M, et al. Influence of IGF-I serum concentration on muscular regeneration capacity in patients with sarcopenia[J]. BMC Musculoskelet Disord, 2021, 22(1): 807.
[12] HUGHES D C, BAEHR L M, WADDELL D S, et al. Ubiquitin ligases in longevity and aging skeletal muscle[J]. Int J Mol Sci, 2022, 23(14): 7602.
[13] AL MAMUN A, UDDIN M S, KABIR M T, et al. Exploring the promise of targeting ubiquitin-proteasome system to combat Alzheimer’s disease[J]. Neurotox Res, 2020, 38(1): 8-17.
[14] KANG M K, PARK J G. Low skeletal muscle mass is a risk factor for subclinical atherosclerosis in patients with nonalcoholic fatty liver disease[J]. Diagnostics, 2021, 11(5): 854.
[15] QUAN Y, WANG C, WANG L, et al. Geriatric sarcopenia is associated with hypertension: a systematic review and meta-analysis[J]. J Clin Hypertens, 2023, 25(9): 808-816.
[16] KWON R J, CHO Y H, PARK E J, et al. Association between pulse pressure and low muscle mass in Korean adults: a nationwide cross-sectional study[J]. Medicine, 2023, 102(52): e36644.
[17] LIN F, PA J, KARIM R, et al. Subclinical carotid artery atherosclerosis and cognitive function in older adults[J]. Alzheimers Res Ther, 2022, 14(1): 63.
[18] JOVIANO-SANTOS J V, KLJAKIC O, MAGALHÃES-GOMES M P S, et al. Motoneuron-specific loss of VAChT mimics neuromuscular defects seen in congenital myasthenic syndrome[J]. FEBS J, 2021, 288(18): 5331-5349.
[19] WU M Y, ZOU W J, LEE D, et al. APP in the neuromuscular junction for the development of sarcopenia and Alzheimer’s disease[J]. Int J Mol Sci, 2023, 24(9): 7809.
[20] MIYAZAKI S, IINO N, KODA R, et al. Brain-derived neurotrophic factor is associated with sarcopenia and frailty in Japanese hemodialysis patients[J]. Geriatr Gerontol Int, 2021, 21(1): 27-33.
[21] WANG Z H, XIANG J, LIU X, et al. Deficiency in BDNF/TrkB neurotrophic activity stimulates δ-secretase by upregulating C/EBPβ in Alzheimer’s disease[J]. Cell Rep, 2019, 28(3): 655-669.
[22] GAO L, ZHANG Y, STERLING K, et al. Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential[J]. Transl Neurodegener, 2022, 11(1): 4.
[23] YOUNG M F, VALARIS S, WRANN C D. A role for FNDC5/Irisin in the beneficial effects of exercise on the brain and in neurodegenerative diseases[J]. Prog Cardiovasc Dis, 2019, 62(2): 172-178.
[24] CHANG J S, KIM T H, NGUYEN T T, et al. Circulating irisin levels as a predictive biomarker for sarcopenia: a cross-sectional community-based study[J]. Geriatr Gerontol Int, 2017, 17(11): 2266-2273.
[25] PEDERSEN B K. Physical activity and muscle-brain crosstalk[J]. Nat Rev Endocrinol, 2019, 15(7): 383-392.
[26] LOURENCO M V, FROZZA R L, DE FREITAS G B, et al. Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer’s models[J]. Nat Med, 2019, 25(1): 165-175.
[27] MOON HYO Y, BECKE A, BERRON D, et al. Running-induced systemic cathepsin B secretion is associated with memory function[J]. Cell Metab, 2016, 24(2): 332-340.
[28] HOOK G, REINHECKEL T, NI J, et al. Cathepsin B gene knockout improves behavioral deficits and reduces pathology in models of neurologic disorders[J]. Pharmacol Rev, 2022, 74(3): 600-629.
[29] NI J, WU Z, STOKA V, et al. Increased expression and altered subcellular distribution of cathepsin B in microglia induce cognitive impairment through oxidative stress and inflammatory response in mice[J]. Aging Cell, 2019, 18(1): e12856.
[30] LEWITT M S, BOYD G W. The role of insulin-like growth factors and insulin-like growth factor-binding proteins in the nervous system[J]. Biochem Insights, 2019, 12: 1-18.
[31] LIN J Y, KUO W W, BASKARAN R, et al. Swimming exercise stimulates IGF1/PI3K/Akt and AMPK/SIRT1/PGC1α survival signaling to suppress apoptosis and inflammation in aging hippocampus[J]. Aging, 2020, 12(8): 6852-6864.
[32] YANG L, WANG H, LIU L, et al. The role of insulin/IGF-1/PI3K/Akt/GSK3β signaling in Parkinson’s disease dementia[J]. Front Neurosci, 2018, 12: 73.
[33] KIM S, CHOI J Y, MOON S, et al. Roles of myokines in exercise-induced improvement of neuropsychiatric function[J]. Pflugers Arch, 2019, 471(3): 491-505.
[34] COLLELUORI G, VILLAREAL D T. Aging, obesity, sarcopenia and the effect of diet and exercise intervention[J]. Exp Gerontol, 2021, 155: 111561.
[35] MARTíNEZ-ARNAU F M, FONFRíA-VIVAS R, CAULI O. Beneficial effects of leucine supplementation on criteria for sarcopenia: a systematic review[J]. Nutrients, 2019, 11(10): 2504.
[36] NUZUM H, STICKEL A, CORONA M, et al. Potential benefits of physical activity in MCI and dementia[J]. Behav Neurol, 2020, 2020: 7807856.
[37] BO Y, LIU C, JI Z, et al. A high whey protein, vitamin D and E supplement preserves muscle mass, strength, and quality of life in sarcopenic older adults: a double-blind randomized controlled trial[J]. Clin Nutr, 2019, 38(1): 159-164.
[38] AROSIO B, ROSSI P D, FERRI E, et al. Characterization of Vitamin D status in older persons with cognitive impairment[J]. Nutrients, 2022, 14(6): 1142.
[39] CASATI M, BOCCARDI V, FERRI E, et al. Vitamin E and Alzheimer’s disease: the mediating role of cellular aging[J]. Aging Clin Exp Res, 2020, 32(3): 459-464.
[40] BUONDONNO I, SASSI F, CARIGNANO G, et al. From mitochondria to healthy aging: the role of branched-chain amino acids treatment: MATeR a randomized study[J]. Clin Nutr, 2020, 39(7): 2080-2091. |
